Contrasting roles of leukemia inhibitory factor in murine bone development and remodeling involve region-specific changes in vascularization

Journal of Bone and Mineral Research

Volumn 27, Issue 3, 2012, Pages 586-595

  Poulton, Ingrid J ^a   McGregor, Narelle E ^a   Pompolo, Sueli ^a   Walker, Emma C ^a   Sims, Natalie A ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

ENDOCHONDRAL OSSIFICATION; GP130; LEUKEMIA INHIBITORY FACTOR; OSTEOBLAST; OSTEOCLAST

Indexed keywords

LEUKEMIA INHIBITORY FACTOR; VASCULOTROPIN;

ADIPOCYTE; ADIPOGENESIS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; BONE CELL; BONE DEVELOPMENT; BONE REMODELING; CARTILAGE; CELL DIFFERENTIATION; CHONDROCLAST; CONTROLLED STUDY; FEMALE; GROWTH PLATE; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; VASCULARIZATION;

ADIPOCYTES; ANIMALS; ANIMALS, NEWBORN; BLOOD VESSELS; BONE AND BONES; BONE DEVELOPMENT; BONE REMODELING; FEMALE; GROWTH PLATE; LEUKEMIA INHIBITORY FACTOR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857312108     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1485     Document Type: Article

References (39)

1. Martin TJ, Sims NA., Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005; 11 (2): 76-81.
2. Nordahl J, Andersson G, Reinholt FP., Chondroclasts and osteoclasts in bones of young rats: comparison of ultrastructural and functional features. Calcif Tissue Int. 1998; 63 (5): 401-8.
3. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ., Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest. 2004; 113 (3): 379-89.
4. Allan EH, Hilton DJ, Brown MA, Evely RS, Yumita S, Metcalf D, Gough NM, Ng KW, Nicola NA, Martin TJ., Osteoblasts display receptors for and responses to leukemia-inhibitory factor. J Cell Physiol. 1990; 145 (1): 110-9.
5. Grimaud E, Blanchard F, Charrier C, Gouin F, Redini F, Heymann D., Leukaemia inhibitory factor (lif) is expressed in hypertrophic chondrocytes and vascular sprouts during osteogenesis. Cytokine. 2002; 20 (5): 224-30.
6. Dagoneau N, Scheffer D, Huber C, Al-Gazali LI, Di Rocco M, Godard A, Martinovic J, Raas-Rothschild A, Sigaudy S, Unger S, Nicole S, Fontaine B, Taupin JL, Moreau JF, Superti-Furga A, Le Merrer M, Bonaventure J, Munnich A, Legeai-Mallet L, Cormier-Daire V., Null leukemia inhibitory factor receptor (LIFR) mutations in Stüve-Wiedemann/Schwartz-Jampel type 2 syndrome. Am J Hum Genet. 2004; 74 (2): 298-305.
7. Cormier-Daire V, Munnich A, Lyonnet S, Rustin P, Delezoide AL, Maroteaux P, Le Merrer M., Presentation of six cases of Stüve-Wiedemann syndrome. Pediatr Radiol. 1998; 28 (10): 776-80.
8. Jung C, Dagoneau N, Baujat G, Le Merrer M, David A, Di Rocco M, Hamel B, Megarbane A, Superti-Furga A, Unger S, Munnich A, Cormier-Daire V., Stüve-Wiedemann syndrome: long-term follow-up and genetic heterogeneity. Clin Genet. 2010; 77 (3): 266-72.
9. Ware CB, Horowitz MC, Renshaw BR, Hunt JS, Liggitt D, Koblar SA, Gliniak BC, McKenna HJ, Papayannopoulou T, Thoma B, Cheng L, Donovan PJ, Peschon JJ, Bartlett PF, Willis CR, Wright BD, Carpenter MK, Davison BL, Gearing DP., Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development. 1995; 121 (5): 1283-99.
10. Walker EC, McGregor NE, Poulton IJ, Solano M, Pompolo S, Fernandes TJ, Constable MJ, Nicholson GC, Zhang JG, Nicola NA, Gillespie MT, Martin TJ, Sims NA., Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest. 2010; 120 (2): 582-92.
11. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, Kishimoto T, Suda T., Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA. 1993; 90 (24): 11924-8.
12. Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling AF, Komnenovic V, Scheuch H, Priemel M, Stewart CL, Amling M, Wagner EF., Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature. 2008; 454 (7201): 221-5.
13. Cornish J, Callon K, King A, Edgar S, Reid IR., The effect of leukemia inhibitory factor on bone in vivo. Endocrinology. 1993; 132 (3): 1359-66.
14. Sims NA., gp130 signaling in bone cell biology: multiple roles revealed by analysis of genetically altered mice. Mol Cell Endocrinol. 2009; 310 (1-2): 30-9.
15. Sims NA, Walsh NC., GP130 cytokines and bone remodelling in health and disease. BMB Rep. 2010; 43 (8): 513-23.
16. Walker EC, McGregor NE, Poulton IJ, Pompolo S, Allan EH, Quinn JM, Gillespie MT, Martin TJ, Sims NA., Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res. 2008; 23 (12): 2025-32.
17. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG., Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine. 2000; 12 (6): 613-21.
18. Davis S, Aldrich TH, Valenzuela DM, Wong VV, Furth ME, Squinto SP, Yancopoulos GD., The receptor for ciliary neurotrophic factor. Science. 1991; 253 (5015): 59-63.
19. McGregor NE, Poulton IJ, Walker EC, Pompolo S, Quinn JM, Martin TJ, Sims NA., Ciliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodeling. Calcif Tissue Int. 2010; 86 (3): 261-70.
20. Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, Kontgen F, Abbondanzo SJ., Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature. 1992; 359 (6390): 76-9.
21. Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, Gaillard-Kelly M, Baron R., Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone. 2002; 30 (1): 18-25.
22. Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N, Moriggl R, Goffin V, Coschigano K, Gaillard-Kelly M, Kopchick J, Baron R, Kelly PA., Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest. 2000; 106 (9): 1095-103.
23. Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Gillespie MT, Walsh NC, Chia LY, Quinn JM, Martin TJ, Sims NA., Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone. 2010; 46 (6): 1486-97.
24. Sims NA, Brennan K, Spaliviero J, Handelsman DJ, Seibel MJ., Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. Am J Physiol Endocrinol Metab. 2006; 290 (3): E456-62.
25. Horn D, Rivas P, McCluskey B, Mundy GR, Gutierrez G., A new staining technique for undecalcified bone sections that enhances visualization of fluorochromes. J Bone Miner Res. 2002; 17: S416.
26. Sims NA, White CP, Sunn KL, Thomas GP, Drummond ML, Morrison NA, Eisman JA, Gardiner EM., Human and murine osteocalcin gene expression: conserved tissue restricted expression and divergent responses to 1,25-dihydroxyvitamin D3 in vivo. Mol Endocrinol. 1997; 11 (11): 1695-708.
27. Quinn JM, Sims NA, Saleh H, Mirosa D, Thompson K, Bouralexis S, Walker EC, Martin TJ, Gillespie MT., IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol. 2008; 181 (8): 5720-9.
28. Allan EH, Ho PW, Umezawa A, Hata J, Makishima F, Gillespie MT, Martin TJ., Differentiation potential of a mouse bone marrow stromal cell line. J Cell Biochem. 2003; 90 (1): 158-69.
29. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE., Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA. 2001; 98 (10): 5804-8.
30. Allan EH, Hausler KD, Wei T, Gooi JH, Quinn JM, Crimeen-Irwin B, Pompolo S, Sims NA, Gillespie MT, Onyia JE, Martin TJ., EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res. 2008; 23 (8): 1170-81.
31. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F., Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. Embo J. 1994; 13 (5): 1189-96.
32. Sims NA, Jenkins BJ, Nakamura A, Quinn JM, Li R, Gillespie MT, Ernst M, Robb L, Martin TJ., Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res. 2005; 20 (7): 1093-102.
33. Quach JM, Walker EC, Allan E, Solano M, Yokoyama A, Kato S, Sims NA, Gillespie MT, Martin TJ., Zinc finger protein 467 is a novel regulator of osteoblast and adipocyte commitment. J Biol Chem. 2011; 286 (6): 4186-98.
34. Sabatakos G, Sims NA, Chen J, Aoki K, Kelz MB, Amling M, Bouali Y, Mukhopadhyay K, Ford K, Nestler EJ, Baron R., Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med. 2000; 6 (9): 985-90.
35. Kubota Y, Hirashima M, Kishi K, Stewart CL, Suda T., Leukemia inhibitory factor regulates microvessel density by modulating oxygen-dependent VEGF expression in mice. J Clin Invest. 2008; 118 (7): 2393-403.
36. Maes C, Goossens S, Bartunkova S, Drogat B, Coenegrachts L, Stockmans I, Moermans K, Nyabi O, Haigh K, Naessens M, Haenebalcke L, Tuckermann JP, Tjwa M, Carmeliet P, Mandic V, David JP, Behrens A, Nagy A, Carmeliet G, Haigh JJ., Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. Embo J. 2010; 29 (2): 424-41.
37. Mizoguchi T, Muto A, Udagawa N, Arai A, Yamashita T, Hosoya A, Ninomiya T, Nakamura H, Yamamoto Y, Kinugawa S, Nakamura M, Nakamichi Y, Kobayashi Y, Nagasawa S, Oda K, Tanaka H, Tagaya M, Penninger JM, Ito M, Takahashi N., Identification of cell cycle-arrested quiescent osteoclast precursors in vivo. J Cell Biol. 2009; 184 (4): 541-54.
38. Hogan JC, Stephens JM., Effects of leukemia inhibitory factor on 3T3-L1 adipocytes. J Endocrinol. 2005; 185 (3): 485-96.
39. Shin HI, Divieti P, Sims NA, Kobayashi T, Miao D, Karaplis AC, Baron R, Bringhurst R, Kronenberg HM., Gp130-mediated signaling is necessary for normal osteoblastic function in vivo and in vitro. Endocrinology. 2004; 145 (3): 1376-85.